The estimated Net Worth of Aaron Van Devender is at least 55.3 千$ dollars as of 25 November 2022. Aaron Devender owns over 150,000 units of Applied Molecular Transport stock worth over 55,291$ and over the last 4 years Aaron sold AMTI stock worth over 0$.
Aaron has made over 2 trades of the Applied Molecular Transport stock since 2022, according to the Form 4 filled with the SEC. Most recently Aaron bought 150,000 units of AMTI stock worth 150,000$ on 25 November 2022.
The largest trade Aaron's ever made was buying 150,000 units of Applied Molecular Transport stock on 25 November 2022 worth over 150,000$. On average, Aaron trades about 28,571 units every 39 days since 2020. As of 25 November 2022 Aaron still owns at least 212,659 units of Applied Molecular Transport stock.
You can see the complete history of Aaron Devender stock trades at the bottom of the page.
Aaron's mailing address filed with the SEC is AMTI, C/O CORPORATION TRUST COMPANY,, TRUST CENTER, 1209 ORANGE ST., WILMINGTON, DE, 19801.
Over the last 4 years, insiders at Applied Molecular Transport have traded over 9,673,149$ worth of Applied Molecular Transport stock and bought 3,091,278 units worth 40,384,206$ . The most active insiders traders include Capital Group, Llcepq Llc A...、Helen Susan Kim、Tahir Ph.D. Mahmood. On average, Applied Molecular Transport executives and independent directors trade stock every 24 days with the average trade being worth of 26,155$. The most recent stock trade was executed by Tahir Ph.D. Mahmood on 22 November 2023, trading 286,320 units of AMTI stock currently worth 45,811$.
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It is also involved in developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase Ia clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Applied Molecular Transport executives and other stock owners filed with the SEC include: